European canine lymphoma network consensus recommendations for reporting flow cytometry in canine hematopoietic neoplasms by Comazzi, S et al.
Regional spotlight 
EUROPEAN CANINE LYMPHOMA NETWORK CONSENSUS RECOMMENDATIONS FOR REPORTING FLOW 
CYTOMETRY IN CANINE HEMATOPOIETIC NEOPLASMS 
Comazzi S.1, Avery PR2, Garden OA3, Riondato F4, Rütgen B5, Vernau W6, on behalf of the European Canine 
Lymphoma Network 
 
Running title: reporting flow cytometry in canine lymphoma 
 
1 Department of Veterinary Science and Public Health, University of Milan, Milan, IT,  
2 Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, US,  
3 Immune Regulation Laboratory, Department of Clinical Science and Services, Royal Veterinary College, 
London, UK  
4 Department of Veterinary Sciences, University of Turin, Turin, IT,  
5 Clinical Pathology, Department of Pathobiology, University of Veterinary Medicine Vienna, AT,  
6 Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of 
California-Davis, Davis, CA,US,  
 
Corresponding author: 
Stefano Comazzi 
Department of Veterinary Science and Public Health,  
University of Milan, Italy,  
e-mail: stefano.comazzi@unimi.it, stefano.comazzi@eu-can-lymph.net,  
tel ++39 02 503 18053, Fax ++39 02 503 18095 
 
Keywords, dog, lymphoma, European Canine Lymphoma Network, report, guidelines.  
 
Abstract 
Background: Flow cytometry (FC) is assuming increasing importance in diagnosis in veterinary oncology. 
The European Canine Lymphoma Network (ECLN) is an international cooperation of different institutions 
working on canine lymphoma diagnosis and therapy. The ECLN panel of experts on FC has defined the issue 
of reporting FC on canine lymphoma and leukemia as their first hot topic, since a standardized report that 
includes all the important information is still lacking in veterinary medicine.  
Methods: The flow cytometry panel of the ECLN started a consensus initiative using the Delphi approach. 
Clinicians were considered the main target of FC reports. A panel of experts in FC was interrogated about 
the important information needed from a report.  
Results: Using the feedback from clinicians and subsequent discussion, a list of information to be included 
in the report was made, with four different levels of recommendation. The final report should include both 
a quantitative part and a qualitative or descriptive part with interpretation of the salient results. Other 
items discussed included the necessity of reporting data regarding the quality of samples, use of absolute 
numbers of positive cells, cutoff values, the intensity of fluorescence, and possible aberrant patterns of 
antigen expression useful from a clinical point of view. 
Conclusion: The consensus initiative is a first step towards standardization of diagnostic approach to canine 
hematopoietic neoplasms among different institutions and countries. This harmonization will improve 
communication and patient care and also facilitate the multicenter studies necessary to further our 
knowledge of canine hematopoietic neoplasms. 
  
Introduction 
Flow cytometry (FC) is increasingly being used in veterinary clinical pathology laboratories owing to the 
increasing number of FC facilities, greater availability of specific antibodies labeled with different 
fluorochromes, and the rapidity with which results can be generated. Immunophenotyping hematopoietic 
neoplasms is one of the most important applications of FC in veterinary clinical pathology diagnostics since 
this method rapidly provides useful information on the lineage of neoplastic cells, identifies some specific 
neoplastic subtypes (T zone lymphomas, chronic lymphocytic leukemia) (1-4), accurately defines stage (5) 
and, in some cases, can detect minimal residual disease (6).  
The overall utility of flow cytometry and its role in the diagnostic pathway is dependent on several aspects. 
One aspect is the ability to provide important information to frame the neoplastic disease in the context of 
results of other clinical and laboratory tests. Therefore, a useful FC report should contain all the 
appropriate information required by clinicians, provide improved characterization of the neoplastic disease, 
help determine therapy, and inform a monitoring strategy to enable early detection of relapse. This 
requires sufficient clarity of reporting to allow understanding by non-FC experts. The specific experience of 
the flow cytometrist should help in the interpretation of the results, always in conjunction with signalment, 
clinical presentation, and the results of other laboratory tests. However, an appropriate report should also 
contain all necessary raw data and describe the strategies used to generate them. This provides 
information about reproducibility and facilitates interpretation by other experts in second opinion or multi-
center studies. The balance between these two aspects, the clinician-friendly utility and the inclusion of 
sufficient technical information to represent a rigorous and reproducible analysis, shapes the format of the 
FC report. 
In human medicine, the issue of reporting flow cytometry immunophenotyping has been widely debated 
(7,8) and guidelines have been published and regularly updated (9,10). Until now, there has been no similar 
discussion in veterinary medicine. To the authors’ knowledge, every veterinary FC facility uses its own 
strategy and system in reporting results of immunophenotyping. 
Methods 
The European Canine Lymphoma Network (ECLN) is a network that was created in 2009 with the aim of 
establishing cooperation among different institutions working on canine lymphoma diagnosis and therapy 
(11). The definition of consensus guidelines and approaches is one of the main goals of ECLN and a specific 
panel on FC has been formed gathering 16 participants selected on demonstrated expertise in veterinary 
FC. The ECLN aims to drive the creation of consensus guidelines, possibly interfacing with extra EU 
specialists, in a democratic and inclusive way. The FC panel of the ECLN defined the issue of reporting FC 
immunophenotyping as the first “hot” topic requiring a consensus discussion.  
When attempting to reach a consensus on defined topics using online-based surveys, a tool called the 
Delphi method is considered the best technique (12). This method relies on a series of questionnaires 
provided to the panel participants in ‘rounds’ until answers converge towards a common answer. Only 
statements reaching at least 75% consensus agreement are included in the final document, otherwise 
statements are re-written and additional rounds of questions follow until the threshold agreement level of 
75% is reached. After review of the results of the explorative survey and the relevant reference sources, the 
members of the FC panel are approached through successive rounds of questioning and the answers and 
feedback are collected in an anonymous fashion. The statements passing the threshold are finally 
considered as common recommendations and contribute to the consensus paper.  
The panel of experts in flow cytometry of the ECLN was also interrogated for each piece of information with 
4 different levels of recommendation: mandatory, recommended, additional or irrelevant. Results on the 
percentage of agreement are reported in Table 1 (16/16 responders). Relevance of information was based 
on a 75% response threshold. If >75% of respondents answered “mandatory”, “recommended” or 
“additional” for a specific category without either response necessarily reaching 75% individually, the 
category was considered “relevant”. The consensus level of recommendation was reported if it reached at 
least 50% of agreement among responders. If agreement was less than 50% for any level, the final 
recommendation was reported as “no consensus”.  
Before starting with the discussion on different issues, the panel of experts in FC decided to document the 
perceived needs of clinicians. A preliminary exploratory survey among the members of the ECLN therapy 
working group, consisting of clinicians interested in the study and therapy of canine lymphoma, was 
conducted. The complete results obtained from this survey are not included in detail in the present 
document but were used as a starting draft for the members of the FC panel for discussion in order to 
define the relevance of each component to be submitted to this consensus evaluation  
Results 
Preliminary exploratory survey among the members of the ECLN therapy working group 
Thirty out of 66 clinicians (45%) of the ECLN therapy working group responded to the preliminary survey. 
Most (51.7%) respondents reported requesting FC in more than 80% of lymphoma cases, and  17.2% of 
respondents reported requesting FC in more than 50% but less than 80% of lymphoma cases. Only 24.1% of 
respondents reported the use of FC in less than 20% of lymphoma cases. Most respondents (51.7%) also 
reported sending blood and bone marrow samples for staging in selected cases, while 63.3% stated that 
they usually add smears from blood, bone marrow or lymph node for concurrent cytomorphologic 
evaluation. 
The majority of clinicians (58.6%) reported the definition of the immunophenotype of the neoplasm as the 
main reason for requiring FC, while refining lymphoma subtype (20.7%), definition of prognosis (6.9%), 
checking minimal residual disease (3.4%) and differentiating lymphoma from reactive conditions (3.4%) 
were reasons reported less frequently. 
The minimally invasive nature of sampling (40%), the accuracy in resolving reactive vs. neoplastic conditions 
(16%) and the rapidity of the results (12%) were recognized as the main advantages of FC over other 
techniques. The most important mentioned characteristics required for a flow cytometric report were that 
they should first be both exhaustive and accurate (46.4%) and second, easy to read and interpret (42.9%).  
Results were variable among respondents, indicating that the needs of clinicians are quite heterogeneous. 
However, the following components were considered to be essential information, with a consensus of 
more than 75% of responders: specification of the type of tissue sent, assessment of the quality of the 
sample, reliability of documented marker expression dependent on sample quality, panel of antibodies 
applied and aberrant patterns identified. All the other information (the same detailed in Table 1) was 
generally considered as important or essential (although without 75% consensus), except specification of 
the instrument used for analysis, which was considered irrelevant information by most clinicians. 
Identification of discussion topics  
Two major and eight minor issues were identified and subsequently discussed, the discussion including 
published sources both in human and veterinary medicine. 
1.Major issues 
a. Identification of the “target users and/or recipients” of FC reports and their needs 
The identification of the final “targets” of FC immunophenotyping reporting on canine lymphomas and 
leukemias is crucial for appropriately defining the relevant information to be included in the report.  
Three main “target user and/or recipient groups” with different needs were identified: 1) owners, 
interested in understanding their pet’s disease; 2) clinicians, mainly specialists in oncology, interested in 
characterizing the disease in order to define prognosis, target therapy and monitor follow-up and 3) clinical 
pathologists, sometimes specialists in FC, asked to interpret the results of laboratory tests in an integrated 
way or to provide a second opinion. The relevance and emphasis of each piece of information provided in 
the FC report is variable among these three user groups.  
Clinicians were considered the most important target users of FC reports as they decide if the FC analysis is 
indicated, provide the samples, communicate the results to owners and institute treatment.  
Pet owners were not considered the major target of FC reports since management by the 
clinician/oncologist is the most common situation. They are generally interested in an accurate diagnosis of 
the disease from which their pet is suffering. Bibliographic references to support the diagnosis and better 
clarify the disease biology should be considered optional items in generating a final report. Mentioning the 
operator/specialist’s name and titles should be included as well. 
Finally, other specialists such as clinical pathologists and flow cytometrists were considered possible targets 
of FC reports. Their needs are generally much more related to technical aspects, such as data on gating 
strategies, possible artefactual changes, viability/conservation of the sample, raw percentages (and 
absolute numbers) of neoplastic cells, type of labeling used (multicolor vs monocolor; composition of tubes, 
antibody clones used), and controls. Possibly scattergrams could be used to better clarify some of the 
technical aspects. However, the inclusion of such technical information in the standard FC report could 
appear extraneous and lead to confusion of non-experts in FC. This information should be omitted from the 
standard FC report but could remain available to be provided upon request, including, if necessary, raw FCS 
files.  
b. reporting percentages vs descriptive report 
Percentages and possibly absolute numbers commonly form the basis for FC immunophenotyping. This 
method is considered more objective and accurate; however, a series of problems may be encountered: 1) 
percentages are directly dependent upon gating strategy (scatter properties vs CD45 positive cells vs 
specific subtypes) 2) percentages of positive events do not provide any information regarding co-expression 
3) percentage of positivity is highly dependent on controls used to set cutoff values 4) providing percentage 
of positive events alone often cannot distinguish neoplastic and residual normal cells and 5) percentages of 
positive events may be redundant and may not contribute to clarity and easy interpretation of the results. 
Reporting percentages of positive events in different cell subpopulations, identified upon light scatter or 
immunophenotypic features (for instance high FSC low SSC cells, or CD21 positive cells) may further 
improve accuracy of the report.  
In contrast, a descriptive report may better focus on neoplastic cells, is clearer and easier to interpret, 
avoids redundancies and may provide information on co-expression, aberrant pattern(s) and quantitative 
expression. However, it may be less objective since it is often biased by the interpretation and experience 
of the specialist. It is recommended that objective (percentage of positive cells) and subjective (i.e. 
descriptive interpretation based on experience) statements be clearly identifiable in the report. The 
descriptive report should be conversational and may easily include data from other laboratory tests 
(cytological review, molecular clonality assessment, CBC, etc). 
Consensus was reached regarding the necessity to include both parts in the FC report, with an emphasis on 
the conversational, descriptive part. Data such as the percentages of positive cells should be reported in 
parentheses or in a table attached to the written report. Data about cells not considered important for the 
tumor subtype (for instance myeloid cells in lymphomas, T cell subsets in B cell neoplasms, residual 
lymphoid population in AML) should be reported, but with an effort to clearly identify them as additional 
information (in the conversional part) in order to avoid confusion and redundancies. These data could be 
discussed in more detail if they have been shown to be related to immunity against the tumor or have 
possible prognostic meaning based on published research. 
2 Minor issues 
a. Information regarding the quality of the sample 
Information regarding the quality of the sample is crucial for interpreting the results of analysis and 
identifying any possible sources of bias. Unanimous consensus was reached about the relevance of 
including information regarding the quality of the sample and the evaluation of viability and 
preservation of cells in the report, including the type of technique used. This was considered 
mandatory information by the majority of the participants. These data may be derived from the 
evaluation of scatterplots, the evaluation of viable cells by using specific stains (propidium iodide, 
trypan blue, etc) or using other qualitative methods. Objective methods (propidium iodide or other 
stains) are preferable and results may be reported as percentage of viable cells or with a 
descriptive method. The technique used to assess the quality of the sample should preferably be 
specified in the final report.  
b. Gating strategies 
Although gating strategy used may be considered unnecessary information for clinicians and 
owners, this piece of information could be of use for specialists in order to better interpret results 
and for second opinions. Consensus was reached in considering it as relevant information to be 
possibly included in an FC report but no consensus was reached about the level of 
recommendation.  
c. Dot plot images 
Attaching images of dot plots to final reports could be of some use to other specialists to better 
understand gating strategies. However, they may be of limited use and difficult to interpret for 
most users (clinicians and pet owners) and may lead to potential misinterpretation. In addition, the 
choice of plots (histogram vs dot vs tridimensional) is not standardized and the results of all the 
antibodies used are not easily summarized in a few images. The routine inclusion of dot plots in a 
final report was not favored. Images or preferably .fcs files should be kept and can be provided 
upon request. 
d. Reporting absolute numbers 
Reporting absolute numbers of leukocyte subpopulations may be done by directly counting cells 
with the flow cytometer or by calculating them from flow cytometric percentages and complete 
blood count (CBC) data. Reporting absolute numbers could be useful mainly in blood, while they 
are probably of limited importance in bone marrow and lymph node aspirates in which relative 
percentages (out of CD45 positive cells or total cells) are much more important. When absolute 
numbers are reported, laboratory specific reference intervals should be provided.  
e. Cutoff value 
The cutoff value for considering a neoplastic population positive or negative for a specific antibody 
is another important issue. The determination of the percentage of positive neoplastic cells 
depends on the appropriate negative controls used and may be variable among observers. The use 
of isotype or fluorescence minus one (FMO) controls is strongly encouraged to correctly define 
background staining and fluorescence spillover. An internal control (biological comparison control) 
i.e. a negative population of cells from residual or non-neoplastic cells, is also mandatory to 
correctly define a cutoff value. However, for the sake of clarity, the results of controls should not 
be included in the final report. Some authors (13) suggested 20-30% as the lower limit to define a 
population as positive to a specific antigen but this value has been reconsidered in human 
medicine. Other authors reported positivity as less than 10% of cells = low, 10-50% intermediate, 
>50% = high. No consensus was reached about a cutoff percentage value to define a cell population 
as positive, even though the majority of participants identified 20-30% as an acceptable value. The 
cutoff of positivity may depend upon the tissue analyzed (lymph node vs peripheral blood vs bone 
marrow) and the antigen investigated. The issue of controls and cut-off values was considered a 
crucial issue but beyond the scope of the present consensus paper (reporting flow cytometry 
results). Owing to its critical importance, this issue will be the focus of a future consensus 
document of the ECLN. Regarding this paper, consensus was reached about the need to include 
appropriate controls in the flow cytometric procedure, but inclusion of the control results in the 
final report is not encouraged.  
f. Reporting quantitative antigen expression 
This may be useful for common lineage antigens (CD45, CD44, CD18) or activation antigens (Ki67, 
MHC II) and may provide information about maturation status, aberrant expression or prognosis. In 
dogs, common lineage antigens have been reported to show different expression intensities in 
hematopoietic subsets and different maturation and activation stages (14, 15). MHC II has been 
reported to be associated with prognosis in canine B cell lymphoma (16). Ki67 has been reported to 
be useful in differentiating low and high grade lymphomas (17). Quantitative aberrancies have 
been reported in different lymphoma subtypes (18). Reporting intensities of antigen expression 
may be useful for markers with possible prognostic significance or for those expressed differently 
than expected.  
Quantitative expression is generally reported categorically as bright or dim but this may be 
subjective and poorly repeatable. Some authors reported antigen expression as bright or dim when 
a difference of at least 15% in fluorescence channels was present in the neoplastic population 
compared to the residual population of the same lineage (18). This method is repeatable among 
different laboratories but it is quite complicated and it requires a clear identification of non-
neoplastic residual cells of the same phenotype. Other authors (16) compared Mean Fluorescence 
Index (MFI) of a specific antigen (MHC II) in neoplastic cells to that derived from a cohort of 
neoplastic cases; expression was reported as “dim” if MFI was lower than the 15th percentile of all 
MFI calculated from a large series of canine lymphomas. This method is probably easier but it 
requires a different specific standardization from each laboratory to define the adequate cutoff 
value for fluorescence and a large caseload to calculate appropriate reference values. In addition, 
the expression of some antigens could be compared with those of a non-neoplastic reference 
population clearly identifiable in the sample (such as neutrophils in peripheral blood) (14). This 
method is easy to perform and does not require any specific standardization but it is quite 
subjective and it is based on the assumption that antigen expression remains constant in the 
reference population. Finally, antigen expression could be accurately quantitated using a curve with 
calibrated beads but this method is expensive and difficult to apply to clinical/diagnostic conditions. 
In human medicine, the issue of antigen expression is also crucial. Intensity of staining for some 
antigens may be expressed as bright, dim or negative, and according to their distribution as 
heterogeneous or homogeneous. Some authors also suggest possible reporting of expression as 
weak or strong. Strong refers to unequivocal positivity (not necessarily to bright expression) (8). 
Other authors suggest defining intensity of some antigens as low (when the histogram is 
significantly different but not easily separable from the negative control), middle (when the 
fluorescence peak is contiguous to the negative control but completely distinguishable from it) or 
high (when the fluorescence peak is two or three logarithmic decades higher than the negative 
control) (19). Some antigens (such as ZAP-70 protein in human CLL) are reported comparing MFI of 
neoplastic cells to those of T cells in the same sample. This method is reported as easy to perform 
and optimal for accurately predicting outcome in CLL (20). 
Since no definitive rules on the best way to report fluorescence intensity of antigens in FC reports 
of canine hematopoietic neoplasms have been generated to date, some recommendations are 
proposed: 1) antigen expression may be preferentially expressed as dim or bright and data on 
distribution of the antigen (homogeneous vs heterogeneous) should be provided only if useful to 
discriminate between normal and neoplastic populations, to define subtype, to track 
infiltration/residual disease of neoplastic cells (when quantitative aberrant patterns are present) or 
to define prognosis; 2) when this quantitation is reported, the definition of neoplastic cells as dim 
or bright should be well standardized for each antigen and consistent with methods from published 
references 3) in the absence of specific published references, the criteria used for defining 
quantitative antigen expression (dim vs bright) could be provided in supplementary notes, together 
with the putative biological meaning 4) when possible, quantitative expression of antigens should 
be compared with the closest normal hemic population 5) quantitative findings that are irrelevant 
to clinical importance (i.e. not involving staging, prognosis, minimal residual disease, etc.) should be 
avoided 6) data regarding in-progress studies should be omitted from the diagnostic report until 
they complete the peer-review and publication process. If necessary, references of published FC 
entities could be provided in the notes.  
g. Reporting aberrant patterns  
Qualitatively and or quantitatively aberrant patterns have been reported in several studies in 
different lymphoma subtypes in dogs (18,21,22 ) and may differ from the human counterparts. 
Their importance is far from completely elucidated but, in some cases, specific aberrant patterns 
may be useful to define specific subtypes, or to accurately track neoplastic infiltration in tissues and 
to detect minimal residual disease. In particular, a specific subtype of canine lymphoma with 
peculiar aberrant patterns different from its human counterpart, T zone lymphoma, is well 
recognized. This indolent T cell lymphoma subtype is not uncommon in the dog, in contrast to 
people, and exhibits a characteristic decreased expression of CD45 and frequently the concurrent 
aberrant expression of CD21 (1,2). The likelihood of detecting an aberrant phenotype is linked to 
the number of antibodies used and to the type of labeling and analysis performed (mono- vs multi-
color). Although evidence of the prognostic role of aberrancies in canine hematopoietic neoplasms 
is largely still lacking, it is likely that some specific aberrancies could have a correlation with 
biological behavior, similar to what has been reported in human medicine (23-28). Clinicians are 
often interested in the presence of aberrant patterns, although they may tend to overestimate 
their meaning. The report of percentages of positive cells alone may miss the detection of specific 
aberrant patterns. The presence of a specific aberrant pattern in neoplastic cells should be 
indicated in the descriptive part of the report if it may be useful to document the infiltration of 
neoplastic cells in organs, to monitor therapy and minimal residual disease, to facilitate the early 
detection of relapse or if it may have a specific biological meaning (prognosis, response to therapy, 
etc). 
Adding a statement to the descriptive part of the report regarding possible FC marker(s) to check 
infiltration or monitor follow-up and detect relapse may be helpful and should be encouraged. 
These markers may include single labeling (for instance CD34+ cells in acute leukemias), multiple 
labeling (e.g. CD3+CD45- cells for T zone lymphomas) or fluorescence and morphological aspects 
together (e.g. large CD21+ cells for DLBCL). 
h. Integration of other clinical data  
Moving toward an integrated report including hematologic, cytologic, histopathologic, 
immunohistochemical and molecular biologic data is a major goal. However, the availability of 
results will influence the possibility of a report integrating all of the laboratory results. An 
integrated report including hematologic, cytologic and FC results while waiting for results of other 
ancillary techniques may be a good compromise and is encouraged. 
Proposal of a possible template for reporting FC results 
According to the previously discussed issues, the proposed report for FC immunophenotyping of canine 
hematopoietic neoplasms should include several sections. 
1) Laboratory identification 
2) Patient identification  
3) Type and quality of the sample(s) 
4) Sample preparation and staining  
5) Percentages of positive cells 
6) Descriptive report 
7) Diagnosis and interpretation 
8) Comments and references 
9) Signatures 
For each section some mandatory, recommended and additional information was identified (Table 1). 
Conclusion 
The present paper is a first step towards standardization of the flow cytometric approach for canine 
hematopoietic neoplasms among different institutions and countries. It should help to provide a more 
accurate report to users and support the use of flow cytometric immunophenotyping in the diagnostic 
algorithm for canine lymphoma and leukemia. The creation of consensus documents on other important 
issues, including pre-processing, instrument standardization and maintenance, controls and cut-offs, and 
suggested antibody panels is an ongoing process for the flow cytometry panel of the ECLN. 
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Table 1 legend : 
Results of the consensus survey among ECLN flow cytometry panel on recommended information in 
different sections of a canine hematopoietic neoplasm flow cytometry report. Each piece of information 
was considered “relevant” if more than 75% of responders classified it as “mandatory”, “recommended” or 
“additional". Recommendations for each piece of information reflect the category at which > 50% of 
responders concurred. Failure to achieve these thresholds resulted in a designation of no consensus. 
Relevancy or recommendation scores of 100% are in bold.  
  
 Table 1 
  Percentage of agreement (%) Relevance 
of information 
Recommendation 
  mandatory recommended additional irrelevant 
Laboratory 
identification  
Name of the 
laboratory 
100 0 0 0 Relevant Mandatory 
 Postal address 53 27 13 7 Relevant Mandatory 
 Telephone number 60 40 0 0 Relevant Mandatory 
 e-mail contact 60 40 0 0 Relevant Mandatory 
 Web page 13 47 27 13 Relevant No consensus 
 Authorization 
number or licenses 
20 40 27 13 Relevant No consensus 
        
Patient 
identification 
Date of the report 93 7 0 0 Relevant Mandatory 
 Date of analysis 64 36 0 0 Relevant Mandatory 
 Internal ID code 60 40 0 0 Relevant Mandatory 
 Owner's name 80 13 7 0 Relevant Mandatory 
 Referring physician 
name and 
institution 
53 40 7 0 Relevant Mandatory 
 Species 93 7 0 0 Relevant Mandatory 
 Breed 67 33 0 0 Relevant Mandatory 
 Gender 60 40 0 0 Relevant Mandatory 
 Age 73 27 0 0 Relevant Mandatory 
 Patient name 60 27 7 7 Relevant Mandatory 
 Previous therapy 33 13 54 0 Relevant Additional 
 Clinical history 40 20 40 0 Relevant No consensus 
 Other laboratory 
results (CBC, Diff) 
27 40 33 0 Relevant No consensus 
        
Type and 
quality of the 
sample 
Type of tissue(s) 93 7 0 0 Relevant Mandatory 
 Type of sample 
(aspirate, biopsy, 
blood, fluid, etc) 
73 27 0 0 Relevant Mandatory 
 Quality of the 
sample (estimated) 
73 27 0 0 Relevant Mandatory 
 Sampling data 73 27 0 0 Relevant Mandatory 
 Percentage of 
viable cells 
26 60 13 0 Relevant Recommended 
 Technique used for 
viability estimation 
13 73 13 0 Relevant Recommended 
 Specimen number 33 53 13 0 Relevant Recommended 
        
Cell 
preparation 
and staining 
Antibodies used 87 13 0 0 Relevant Mandatory 
 Cell preparation 
(whole sample, 
scraping, Ficoll, 
RBC lysis) 
20 53 27 0 Relevant Recommended 
 Antibody clone 0 13 60 27 No consensus Additional 
 Fluorochrome 
combination 
0 13 60 27 No consensus Additional 
 Composition of 
tubes 
0 7 73 20 Relevant Additional 
 Type of controls 0 27 60 13 Relevant Additional 
 Instrumentation 0 13 53 33 No consensus Additional 
 Expected 
positivities for each 
antibody 
13 33 40 13 Relevant No consensus 
        
Descriptive 
report 
Qualitative 
description of 
immunophenotype 
of cells of interest 
78 14 7 0 Relevant Mandatory 
 Comment on 
quantitative 
expression of 
relevant markers 
53 27 20 0 Relevant Mandatory 
 Aberrant patterns 67 33 0 0 Relevant Mandatory 
 Information about 
staging 
7 80 13 0 Relevant Recommended 
 Information about 
residual cells 
0 73 27 0 Relevant Recommended 
 Qualitatitive 
description of 
scatter aspects of 
cells of interest 
47 40 13 0 Relevant No consensus 
        
Percentage of 
positive cells 
Percentage of 
positive cells in 
gated population 
53 47 0 0 Relevant Mandatory 
 Percentage of 
positive cells in 
whole population 
29 57 7 7 Relevant Recommended 
 Intensity of staining 
(dim vs bright, 
homogeneous) 
20 60 20 0 Relevant Recommended 
 Absolute count on 
positive cells (in 
peripheral blood 
only) 
20 53 20 13 Relevant Recommended 
 CD4/CD8 ratio 7 27 53 13 Relevant Additional 
 Representation of 
histogram/plot 
7 20 60 13 Relevant Additional 
 Fluorescence index 
(quantitative) 
0 40 47 13 Relevant No consensus 
 Gating procedure 13 33 33 20 Relevant No consensus 
 Reference intervals 
for each antigen 
7 40 47 7 Relevant No consensus 
        
Diagnosis and 
interpretation 
Diagnosis of 
immunophenotype 
100 0 0 0 Relevant Mandatory 
 Lymphoma subtype 
(tentative) 
53 40 7 0 Relevant Mandatory 
 Stage 20 60 7 13 Relevant Recommended 
 Suggested FC 
markers for 
monitoring stage 
and MRD 
0 67 33 0 Relevant Recommended 
 Possible prognostic 
factors 
27 53 20 0 Relevant Recommended 
 Grade (high vs low) 
(tentative) 
40 40 20 0 Relevant No consensus 
        
Comments Clinical and 
outcome 
information 
0 64 36 0 Relevant Recommended 
 Additional tests 
suggested 
0 53 40 7 Relevant Recommended 
 References 0 47 53 0 Relevant Additional 
        
Signatures Party responsible 
for the service 
73 20 7 0 Relevant Mandatory 
 Flow cytometrist 33 47 20 0 Relevant No consensus 
 
 
 
